The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

CD25V Directed Antibody Drug Conjugate

Back

Molecule overview Clinical trials

CD25V Directed Antibody Drug Conjugate

PF-08046032 is an investigational compound. Its safety and efficacy have not been established

Share to an HCP

Overview + Rationale Mechanism of Action Stage of Development

Share to an HCP

Overview + Rationale

PF-08046032 is a vedotin antibody-drug conjugate (ADC) engineered to target and potentially deplete immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment (TME) through direct cytotoxicity.
PF-08046032 is thought to direct delivery of the cytotoxic MMAE (monomethyl auristatin E) vedotin payload to cells expressing CD25 via affinity-tuned binding of the alpha chain of the IL-2 receptor, which is understood to be highly expressed on intratumoral Tregs and lymphoma cells.
Affinity-tuning can enable targeting of CD25hi intratumoral Tregs while sparing peripheral Tregs.
PF-08046032 leverages the MMAE-based vedotin drug linker platform

Mechanism of Action

Stage of Development

Advanced Solid Tumors

Phase 1 Monotherapy and Combination

R/R Hodgkin's Lymphoma

Phase 1 Monotherapy

CD25V Directed Antibody Drug Conjugate

Geo Regions

CD25V Directed Antibody Drug Conjugate

Overview + Rationale

Mechanism of Action

Stage of Development

This information is current as of August 5th 2025.